Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 7/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.38 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2748592 | 0.83 | DYRK1A (0.44) | KIF11EPHX2NPC1RAB9AP2RX1 | |
| SCHEMBL7113815 | 0.83 | LMNA (0.43) | KIF11EPHX2NPC1RAB9AP2RX1 | |
| SCHEMBL5120153 | 0.80 | MAPT (0.50) | KIF11EPHX2NPC1RAB9AP2RX1 | |
| SCHEMBL2994541 | 0.77 | EPHX2 (0.47) | EPHX2KMT2A | |
| SCHEMBL3884988 | 0.77 | ALDH1A1 (0.52) | KIF11NPC1NR3C2KMT2A | |
| SCHEMBL4422986 | 0.76 | RXFP1 (0.43) | EPHX2NPC1RAB9AP2RX1 | |
| SCHEMBL5111352 | 0.76 | NPSR1 (0.44) | EPHX2KMT2A | |
| SCHEMBL5111541 | 0.76 | MEN1 (0.48) | EPHX2NPC1RAB9AKMT2A | |
| SCHEMBL2989155 | 0.75 | GAA (0.47) | KMT2A | |
| SCHEMBL687441 | 0.75 | MAPT (0.52) | EPHX2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776884-B2 | Cyclic derivatives as modulators of chemokine receptors activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-17 | — | — | US | disclosed |
| US-7572813-B2 | Cyclic amide derivative as monocyte chemotactic protein modulator; prevention and treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma; antiinflammatory agents; N-[2-[[(cis) -2-[[1- (4-Chlorophenyl)ethyl]amino]cyclohexyl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-7087604-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060135503-A1 | Cyclic derivatives as modulators of chemokine receptors activity | CHERNEY ROBERT J | 2006-06-22 | — | — | US | disclosed |
| US-20060135502-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CHERNEY ROBERT | 2006-06-22 | — | — | US | disclosed |
| US-7045521-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-05-16 | — | — | US | disclosed |
| US-6706712-B2 | RHEUMATIC DISEASES, MULTIPLE SCLEROSIS, ASTHMA, ANTICHOLESTEROL AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135502-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | KIF11 3299/4885EPHX2 2297/4885NPC1 1069/4885 |
| US-20060135503-A1 | Cyclic derivatives as modulators of chemokine receptors activity | CCL11, CCR1, CCL2 | KIF11 3391/4885EPHX2 2837/4885NPC1 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.